Health Canada has approved Syqe Medical’s metered dose medical cannabis inhaler, the company said. The Syqe inhaler, which uses a cartridge pre-loaded with granulated cannabis, has been available to patients in Israel since June 2019. In September 2019, the company announced that it had signed a deal with TerrAscend for distribution of the device in Canada.
According to Syqe, the inhaler delivers precise doses of THC in increments of 100 μg that allow for use of the device with minimal side effects. The company notes that no adverse reactions have been reported in patients using the Syqe inhaler for a year or more.
Syqe Medical General Manager in Canada Michael Milloy commented, “Before being approved in Canada, the technology used in the Syqe Inhaler went through ten years of research and development, including testing in a variety of research trials. We are proud of the extensive research that went into bringing the inhaler to Canada and the rigorous clinical evidence that supports its use.”
Syqe founder and CEO Perry Davidson said, “Syqe Medical is proud to bring this first-in-class device, which delivers a specific dose of cannabinoids with each inhalation, helping to relieve symptoms with few, if any, adverse reactions. It is our hope that the Syqe Inhaler will help alleviate physician concerns about adverse reactions and psychoactivity when prescribing medical cannabis.”
Read the Syqe press release.
